

# CONTENTS

|   |             |
|---|-------------|
| <b>List of Tables, Figures, and Exhibits</b>                  | <b>ix</b>   |
| <b>Preface</b>  | <b>xiii</b> |
| <b>The Author</b>   | <b>xvi</b>  |
| <b>CHAPTER ONE: INTRODUCTION TO COST-EFFECTIVENESS</b>        | <b>1</b>    |
| Overview  | 1           |
| Why Cost-Effectiveness Is Useful                              | 3           |
| Elements of Cost-Effectiveness Analysis                       | 4           |
| The Cost-Effectiveness Ratio                                  | 8           |
| Why Conduct Cost-Effectiveness Analysis?                      | 9           |
| The Reference Case Analysis                                   | 12          |
| Cost-Effectiveness Analysis and Policy                        | 14          |
| <b>CHAPTER TWO: PRINCIPLES OF COST-EFFECTIVENESS ANALYSIS</b> | <b>19</b>   |
| Overview  | 19          |
| The Perspective of a Cost-Effectiveness Analysis              | 19          |
| Capturing Costs   | 22          |
| Capturing Quality   | 23          |
| Interpreting the Cost-Effectiveness Ratio                     | 27          |
| Types of Economic Analysis                                    | 30          |
| <b>CHAPTER THREE: DEVELOPING A RESEARCH PROJECT</b>           | <b>36</b>   |
| Overview  | 36          |
| Eight Steps to a Perfect Research Project                     | 36          |
| Developing a Research Question                                | 38          |
| Designing Your Analysis                                       | 43          |

|  |            |
|--|------------|
| <b>CHAPTER FOUR: WORKING WITH COSTS</b>                                    | <b>50</b>  |
| Overview   | 50         |
| Opportunity Costs  | 51         |
| Identifying Costs  | 52         |
| Micro-Costing and Gross Costing  | 55         |
| Getting Cost Data  | 57         |
| Using Diagnosis Codes  | 59         |
| Adjusting Costs  | 60         |
| Costs Associated with Pain and Suffering                                   | 69         |
| Assessing the “Relevancy” of Cost Data                                     | 70         |
| Other Cost Considerations  | 71         |
| <b>CHAPTER FIVE: PROBABILITIES AND MODELS</b>                              | <b>75</b>  |
| Overview   | 75         |
| Probabilities  | 75         |
| Decision Analysis Models   | 79         |
| <b>CHAPTER SIX: CALCULATING LIFE EXPECTANCY</b>                            | <b>87</b>  |
| Overview   | 87         |
| Hand-Calculating Years Gained  | 88         |
| Calculating Life Years Lost Using Markov Models                            | 92         |
| <b>CHAPTER SEVEN: WORKING WITH HEALTH-RELATED QUALITY-OF-LIFE MEASURES</b> | <b>104</b> |
| Overview   | 104        |
| Framework  | 105        |
| Deriving HRQL Scores   | 108        |
| Other Considerations and Reminders   | 115        |
| Using Disability-Adjusted Life Years                                       | 116        |
| <b>CHAPTER EIGHT: CALCULATING QALYs</b>                                    | <b>117</b> |
| Overview   | 117        |
| Using the Summation Method   | 118        |
| Using the Life Table Method  | 119        |
| Calculating Incremental Cost-Effectiveness                                 | 132        |
| Disability-Adjusted Life Year (DALY)                                       | 136        |

|  |            |
|--|------------|
| <b>CHAPTER NINE: CONDUCTING A SENSITIVITY ANALYSIS</b>   | <b>137</b> |
| Overview   | 137        |
| One-Way Sensitivity Analysis                             | 139        |
| Two-Way Sensitivity Analysis                             | 142        |
| Analysis of Influence                                    | 143        |
| Monte Carlo Simulation                                   | 143        |
| Determining the Plausible Range of Each Variable         | 147        |
| <br>   |            |
| <b>CHAPTER TEN: PREPARING YOUR STUDY FOR PUBLICATION</b> | <b>149</b> |
| Overview   | 149        |
| Content and Structure of Cost-Effectiveness Articles     | 149        |
| Introduction   | 151        |
| Methods  | 151        |
| Results  | 153        |
| Technical Appendix                                       | 154        |
| <br>   |            |
| <b>CHAPTER ELEVEN: WORKING WITH DATA</b>                 | <b>155</b> |
| Overview   | 155        |
| Review of Rates  | 156        |
| Understanding Error                                      | 160        |
| Managing Error in Cost-Effectiveness Analysis            | 162        |
| Calculating Weighted Means                               | 168        |
| Evaluating Study Limitations                             | 170        |
| <br>   |            |
| <b>CHAPTER TWELVE: FINDING THE DATA YOU NEED</b>         | <b>179</b> |
| Overview   | 179        |
| Finding Data in the Medical Literature                   | 180        |
| Grading Published Data                                   | 180        |
| Using Electronic Datasets                                | 180        |
| Using Unpublished Data                                   | 188        |
| Using Data from Piggybacked Studies                      | 188        |
| Using Expert Opinion                                     | 189        |
| Organizing Your Data                                     | 189        |

|   |            |
|---|------------|
| <b>Appendix A: Answer Key to Exercises</b>  | <b>191</b> |
| <b>Appendix B: Life Expectancy and Quality-Adjusted Life Expectancy Tables</b>  | <b>197</b> |
| <b>Appendix C: EuroQol Instrument and Weighting Scheme</b>  | <b>201</b> |
| <b>Appendix D: Diagnosis, Charges, Medicare Reimbursement, Average Length of Stay, and Cost-to-Charge Ratio by Diagnosis-Related Groups, 2004</b> | <b>203</b> |
| <b>Glossary</b>   | <b>249</b> |
| <b>References</b>   | <b>255</b> |
| <b>Index</b>  | <b>259</b> |

# TABLES, FIGURES, & EXHIBITS

## TABLES

|      |  |     |
|------|--|-----|
| 1.1. | Hypothetical League Table for a Village in Malawi with a \$58,000 Health Budget  | 16  |
| 2.1. | Costs Included in a Cost-Effectiveness Analysis of Free Contraception, Conducted from Three Perspectives                 | 21  |
| 2.2. | Hypothetical Differences in Health-Related Quality of Life over Ten Years for Diabetic Women and Women in Perfect Health | 25  |
| 2.3. | Decision Matrix for Various Cost-Effectiveness Scenarios   | 30  |
| 4.1. | Partial List of Costs for Treatment of Influenza Infection   | 56  |
| 4.2. | Common Codes Used to Group Diseases  | 59  |
| 4.3. | Medpar Cost Data by DRG  | 62  |
| 4.4. | Medical Portion of the Consumer Price Index 1995–2005, Annual Percentage Change on Previous Year                         | 65  |
| 4.5. | Hypothetical and Discounted Costs of a Cohort of 1,000 Elderly Persons over Ten Years                                    | 68  |
| 6.1. | Number of Deaths Due to Influenza Virus Infection, by Age Group  | 89  |
| 6.2. | Deaths, Mean Age of Death Due to Influenza Virus Infection, and Life Expectancy for Persons Aged 15 to 65                | 89  |
| 6.3. | Calculating Total Years of Life Lost Due to Influenza Virus Infection in the United States                               | 91  |
| 6.4. | Total Deaths, Deaths Due to Influenza Virus Infection, and Total Survivors in a Cohort of 1 Million 15 Year Olds         | 93  |
| 6.5. | Total Person-Years Lived by the Cohort of 1 Million 15 Year Olds   | 95  |
| 6.6. | Person-Years Lived Among the Cohort of 15 Year Olds, Including and Excluding Deaths Due to Influenza Virus Infection     | 96  |
| 6.7. | Age-Specific Mortality Rates, Survivors, and Number of Deaths in the Cohort of 1 Million 15-Year-Old Subjects            | 97  |
| 6.8. | Progression of a Cohort of Ten Women with Breast Cancer over a Six-Year Period   | 100 |
| 7.1. | Example of How an HRQL Score for Influenza Illness May Be Derived Using the EuroQol                                      | 113 |

## X Tables, Figures, & Exhibits

|       |  |     |
|-------|--|-----|
| 8.1.  | Total Person-Years Lived by the Cohort of 1 Million 15 Year Olds   | 120 |
| 8.2.  | Sum of Person-Years Across Age Groups for the Cohort of 1 Million 15 Year Olds   | 122 |
| 8.3.  | Calculating Life Expectancy at a Given Age   | 123 |
| 8.4.  | Abridged Life Table for 2003   | 124 |
| 8.5.  | A Quality-Adjusted Life Table  | 126 |
| 10.1. | Cost-Effectiveness Table   | 153 |
| 11.1. | Hypothetical Example of Two Populations with Equal Numbers of Subjects and Identical Age-Specific Mortality Rates, But Different Population Distributions by Age | 157 |
| 11.2. | Frequency Distribution of Hypothetical Cholesterol Values Obtained from 100 Subjects   | 163 |
| 12.1. | Datasets Useful for Finding Frequently Needed Cost-Effectiveness Parameters  | 185 |

## FIGURES

|      |  |    |
|------|--|----|
| 1.1. | Example of the Effect of a Health Intervention on the Health States of Patients Admitted to the Emergency Room for an Acute Asthma Attack  | 5  |
| 1.2. | Components of a Cost-Effectiveness Analysis  | 6  |
| 2.1. | Graphical Representation of an HRQL Score  | 24 |
| 3.1. | Flowchart Indicating the Clinical Course of Influenza Illness  | 45 |
| 3.2. | Flowchart Indicating the Course of Influenza Infection Among Subjects Who Receive a Vaccination  | 46 |
| 3.3. | Probability of Seeing a Doctor Among Subjects Who Receive Vaccination Versus Those Who Receive Supportive Care                             | 47 |
| 3.4. | Vaccination Strategy Represented with All Probabilities Filled In  | 48 |
| 3.5. | Vaccination Decision Node  | 48 |
| 4.1. | Partial Flowchart of the Course of the Flu   | 53 |
| 4.2. | Costs Associated with the “Does Not See Doctor” Box  | 54 |
| 5.1. | Course of Events During an Influenza Season Among Those Receiving Supportive Care Alone  | 76 |
| 5.2. | Course of Events During an Influenza Season Among Those Receiving a Vaccination  | 77 |
| 5.3. | Total Cost of the Vaccination and Supportive Care Strategies After Incorporating the Probability of Becoming Infected with Influenza Virus | 78 |

|      |  |     |
|------|--|-----|
| 5.4. | Supportive Care Versus Vaccination Decision (Figure 5.3)<br>Represented as a Decision Analysis Tree                                    | 80  |
| 5.5. | Event Pathway for Vaccination Versus Supportive Care Represented<br>as a Decision Analysis Tree  | 81  |
| 5.6. | Decision Analysis Tree Rolled Back to Reveal the Total Cost of Each<br>Strategy in the Influenza Example                               | 83  |
| 6.1. | Basic Concept of a Markov Model  | 98  |
| 6.2. | Complete Decision Analysis Tree for Calculating Life<br>Expectancy Using DATA  | 101 |
| 6.3. | A Rolled-Back Model Using the Probability of Death for<br>the General U.S. Population  | 102 |
| 7.1. | Trade-Off Between the Status Quo Health State and a Gamble   | 107 |
| 7.2. | Diabetes Markov Model Depicting Three Health States: Mild,<br>Moderate, and Severe Diabetes  | 111 |
| 8.1. | Year-to-Year Progress of Treated and Untreated Subjects with<br>Leishmaniasis  | 119 |
| 8.2. | Basic Markov Model Used to Calculate Life Expectancy   | 129 |
| 8.3. | Markov Models Designed to Calculate the Life Expectancy<br>of Subjects Receiving the Filmore and Reinkenshein Procedures               | 130 |
| 8.4. | Difference in HRQL Among Subjects Who Received the<br>Filmore or Reinkenshein Procedure  | 131 |
| 8.5. | Filmore versus Reinkenshein Model Rolled Back to Reveal Gains<br>in Quality-Adjusted Life Expectancy Associated with Each Strategy     | 132 |
| 8.6. | Filmore versus Reinkenshein Model with Costs Added   | 133 |
| 8.7. | Filmore versus Reinkenshein Model with Discounting Added<br>to the HRQL Values   | 134 |
| 8.8. | Filmore versus Reinkenshein Model Rolled Back  | 135 |
| 9.1. | Terminal Branch of the Filmore Arm Represented in Figure 8.3   | 139 |
| 9.2. | Incremental Effectiveness of the Reinkenshein Procedure Relative<br>to the Filmore Procedure over a Range of Risk Ratios               | 140 |
| 9.3. | One-Way Sensitivity Analysis Examining How the Cost of<br>Providing the Influenza Vaccine Influences the Cost of Each Intervention     | 141 |
| 9.4. | Two-Way Sensitivity Analysis Comparing Changes in the Efficacy<br>of the Influenza Vaccine and the Incidence of Influenza-Like Illness | 142 |
| 9.5. | Chance of Incurring Any Given Value of a Normally<br>Distributed Variable  | 144 |
| 9.6. | Diabetes Model in Which Values of Each Variable Are<br>Normally Distributed  | 145 |

|        |   |     |
|--------|---|-----|
| 9.7.   | The Triangular Distribution   | 147 |
| 11.1.  | Nonrandom Error   | 161 |
| 11.2.  | Random Error  | 161 |
| 11.3.  | Graphical Representation of the 100 Cholesterol Values in Table 11.2    | 164 |
| 11.4.  | Probability Distribution of the 100 Cholesterol Values in Table 11.2    | 164 |
| 11.5.  | Hypothetical Probability Distribution of 1,000 Cholesterol Test Results | 166 |
| 11.6.  | The Normal Curve  | 167 |
| 11.7.  | Example of a Triangular Distribution                                    | 169 |
| 11.8.  | Retrospective Study Design  | 171 |
| 11.9.  | Prospective Study Design  | 172 |
| 11.10. | Randomized Controlled Trial Study Design                                | 174 |

## **EXHIBITS**

|       |   |     |
|-------|---|-----|
| 2.1.  | Summary Recommendations for the Correct Placement of Costs in a Cost-Effectiveness Analysis | 27  |
| 7.1.  | EuroQol 5D Health Domains   | 109 |
| 12.1. | Major U.S. Health Datasets Available to the Public  | 181 |
| 12.2. | Major Sources of International Health Data  | 183 |
| 12.3. | Some Data Sources for Which Data Extraction Tools Are Available                             | 186 |